

Expected Financial Impact

Extend Health - Full Year FY12 Forecast	
Revenues	\$67 million
Revenue Growth Rate	31%
EBITDA Margin	22%
Extend Health - Full Year FY13 Outlook	
Revenue Growth Rate (net of deferred revenue adjustment)	Around 30% or more
Deferred Revenue Adjustment	Up to \$15 million
Towers Watson – First Fiscal Year Impact	
Transaction Costs	Approximately \$15 million <i>(transaction costs are excluded on an adjusted EPS basis)</i>
TW Adjusted EPS	Slightly Dilutive
TW Adjusted EBITDA %	Neutral to our target range